Transdermal granisetron

Details Transdermal granisetron Transdermal granisetron

2004-02-05

2009-10-27

Tran, S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

C424S445000, C424S446000, C424S447000, C424S449000

Reexamination Certificate

active

07608282

ABSTRACT:
Adhesive patches for the transdermal administration of granisetron, comprise an acrylic adhesive containing non-acidic nucleophilic moieties which substantially increase flux of granisetron across the skin.

REFERENCES:
patent: 3269994 (1966-08-01), Horn et al.
patent: 5656286 (1997-08-01), Miranda et al.
patent: 2 341 998 (2002-09-01), None
patent: 1 163 902 (2001-12-01), None
patent: WO 9401095 (1994-01-01), None
patent: WO 94/07468 (1994-04-01), None
patent: WO 98/53815 (1998-12-01), None
patent: WO 9853815 (1998-12-01), None
patent: WO 00/47208 (2000-08-01), None
patent: WO 0047208 (2000-08-01), None
patent: WO 01/74338 (2001-10-01), None
Biswas and Rudra, Comparison of granisetron and granisetron plus dexamethasone for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Acta Anaesthesiol Scand., 47:79- 83, 2003.
Cupissol et al., Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for a malignant disease. J.Pharm.Sci., 82:1281-1284, 1993.
Friedman et al., Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. Oncologist, 5:136-143, 2000.
Gralla et al., Recommendations for the use of antiemetics: Evidence based, clinical practice guidelines. Journal of Clinical Oncology, 17:2971-2994, 1999.
Guillem et al., High efficacy of oral granisetron in the total control of cyclophosphamide-induced prolonged emesis. Proceedings of the American Society of Oncology, 17:46, 1998.
Kalaycio et al., Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. J. Cancer Res. Clin. Oncol., 124:265-269, 1998.
Noble et al., a double-blind, randomized, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur. J. of Cancer, 30: 1083-1088, 1994.
Physicians Desk Reference (2001) entry for Kytril®.
Porzio et al., Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron. Support Care Cancer, Jan. 21, 2004.

Affiliated with

Also associated with

Rating

Transdermal granisetron does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transdermal granisetron, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal granisetron will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4143012